Mark A. Wingertzahn

2.1k total citations
55 papers, 1.6k citations indexed

About

Mark A. Wingertzahn is a scholar working on Physiology, Immunology and Allergy and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark A. Wingertzahn has authored 55 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Physiology, 21 papers in Immunology and Allergy and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark A. Wingertzahn's work include Asthma and respiratory diseases (22 papers), Allergic Rhinitis and Sensitization (21 papers) and Respiratory and Cough-Related Research (12 papers). Mark A. Wingertzahn is often cited by papers focused on Asthma and respiratory diseases (22 papers), Allergic Rhinitis and Sensitization (21 papers) and Respiratory and Cough-Related Research (12 papers). Mark A. Wingertzahn collaborates with scholars based in United States, Japan and United Kingdom. Mark A. Wingertzahn's co-authors include Michael S. Blaiss, Eli O. Meltzer, M. Jennifer Derebery, Saul Teichberg, John Boyle, Alfred E. Slonim, Andrew Simmons, Bruce R. Gordon, Ketan Sheth and Todd A. Mahr and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Clinical Infectious Diseases.

In The Last Decade

Mark A. Wingertzahn

55 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark A. Wingertzahn United States 19 863 766 280 195 163 55 1.6k
Salvatore Barberi Italy 18 451 0.5× 428 0.6× 291 1.0× 27 0.1× 56 0.3× 59 1.4k
Giuseppe Di Cara Italy 22 559 0.6× 466 0.6× 192 0.7× 25 0.1× 210 1.3× 101 1.7k
A. Lanteaume France 24 704 0.8× 799 1.0× 264 0.9× 17 0.1× 53 0.3× 49 1.7k
Mar Guilarte Spain 26 498 0.6× 531 0.7× 59 0.2× 43 0.2× 76 0.5× 74 2.5k
Lyndon E. Mansfield United States 22 971 1.1× 771 1.0× 522 1.9× 99 0.5× 15 0.1× 87 1.8k
K. de Vries Netherlands 21 1.3k 1.5× 599 0.8× 928 3.3× 36 0.2× 24 0.1× 61 2.0k
Hanne Vanheel Belgium 18 478 0.6× 158 0.2× 87 0.3× 42 0.2× 94 0.6× 40 2.1k
Robert J. Dockhorn United States 31 2.3k 2.7× 1.4k 1.8× 1.6k 5.7× 204 1.0× 24 0.1× 75 2.9k
T. Frediani Italy 16 361 0.4× 559 0.7× 132 0.5× 14 0.1× 60 0.4× 37 1.1k
Ko‐Huang Lue Taiwan 18 439 0.5× 350 0.5× 158 0.6× 26 0.1× 15 0.1× 47 896

Countries citing papers authored by Mark A. Wingertzahn

Since Specialization
Citations

This map shows the geographic impact of Mark A. Wingertzahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Wingertzahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Wingertzahn more than expected).

Fields of papers citing papers by Mark A. Wingertzahn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Wingertzahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Wingertzahn. The network helps show where Mark A. Wingertzahn may publish in the future.

Co-authorship network of co-authors of Mark A. Wingertzahn

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Wingertzahn. A scholar is included among the top collaborators of Mark A. Wingertzahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Wingertzahn. Mark A. Wingertzahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wolfe, Cameron R., Jonathan Cohen, Anna Holmes, et al.. (2025). Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY). Clinical Infectious Diseases. 81(3). 439–450. 1 indexed citations
2.
Meltzer, Eli O., Michael S. Blaiss, Robert M. Naclerio, et al.. (2012). Burden of allergic rhinitis: Allergies in America, Latin America, and Asia-Pacific adult surveys. Allergy and Asthma Proceedings. 33(5). 113–141. 201 indexed citations
3.
Ratner, Paul H., Mark A. Wingertzahn, Rolf Herzog, et al.. (2011). An investigation of the pharmacokinetics, pharmacodynamics, safety, and tolerability of ciclesonide hydrofluoroalkane nasal aerosol in healthy subjects and subjects with perennial allergic rhinitis. Pulmonary Pharmacology & Therapeutics. 24(4). 426–433. 4 indexed citations
4.
Meltzer, Eli O., Michael S. Blaiss, M. Jennifer Derebery, et al.. (2009). Burden of allergic rhinitis: Results from the Pediatric Allergies in America survey. Journal of Allergy and Clinical Immunology. 124(3). S43–S70. 406 indexed citations
5.
LaForce, Craig, Julius van Bavel, Eli O. Meltzer, & Mark A. Wingertzahn. (2009). Efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol once daily for the treatment of seasonal allergic rhinitis. Annals of Allergy Asthma & Immunology. 103(2). 166–173. 6 indexed citations
6.
7.
Berger, William E., Anjuli Nayak, Bobby Q. Lanier, et al.. (2008). Efficacy and Safety of Once-Daily Ciclesonide Nasal Spray in Children With Allergic Rhinitis. Pediatric Asthma Allergy & Immunology. 21(2). 73–82. 9 indexed citations
8.
Kim, Kenneth, Ruediger Nave, Paul H. Ratner, et al.. (2007). Safety of Once-Daily Ciclesonide Nasal Spray in Children 2 to 5 Years of Age with Perennial Allergic Rhinitis. Pediatric Asthma Allergy & Immunology. 20(4). 229–242. 14 indexed citations
9.
Sato, Hideyuki, Ruediger Nave, Takashi Nonaka, et al.. (2007). Uptake and metabolism of ciclesonide and retention of desisobutyryl-ciclesonide for up to 24 hours in rabbit nasal mucosa. BMC Pharmacology. 7(1). 7–7. 13 indexed citations
10.
Ratner, Paul H., Patrick Darken, Mark A. Wingertzahn, & Tushar Shah. (2007). Ciclesonide and Beclomethasone Dipropionate Coadministration: Effect on Cortisol in Perennial Allergic Rhinitis. Journal of Asthma. 44(8). 629–633. 6 indexed citations
11.
Meltzer, Eli O., Nancy Hall, Mark A. Wingertzahn, et al.. (2007). Efficacy and safety of ciclesonide, 200 μg once daily, for the treatment of perennial allergic rhinitis. Annals of Allergy Asthma & Immunology. 98(2). 175–181. 27 indexed citations
12.
Ratner, Paul H., et al.. (2006). Effectiveness of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis. Annals of Allergy Asthma & Immunology. 97(5). 657–663. 25 indexed citations
13.
Ratner, Paul H., et al.. (2006). Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology. 118(5). 1142–1148. 52 indexed citations
14.
Wingertzahn, Mark A., et al.. (2005). Comparison of nasal tissue concentrations in rabbits following administration of hypotonic and isotonic ciclesonide suspensions. Journal of Allergy and Clinical Immunology. 115(2). S126–S126. 9 indexed citations
15.
Wingertzahn, Mark A., et al.. (2000). Development of the Intestinal SGLT1 Transporter in Rats. Molecular Genetics and Metabolism. 69(3). 233–239. 15 indexed citations
16.
Teichberg, Saul, et al.. (1999). Effect of Gum Arabic in an Oral Rehydration Solution on Recovery From Diarrhea in Rats. Journal of Pediatric Gastroenterology and Nutrition. 29(4). 411–417. 31 indexed citations
17.
Wingertzahn, Mark A. & Raymond S. Ochs. (1999). Changes in Ryanodine Receptor‐Mediated Calcium Release During Skeletal Muscle Differentiation. Proceedings of The Society for Experimental Biology and Medicine. 221(3). 234–241. 11 indexed citations
18.
Wapnir, Raul A., et al.. (1998). Proabsorptive Effects of Modified Tapioca Starch as an Additive of Oral Rehydration Solutions. Journal of Pediatric Gastroenterology and Nutrition. 27(1). 17–22. 1 indexed citations
19.
Wapnir, Raul A., et al.. (1998). Proabsorptive Effects of Modified Tapioca Starch as an Additive of Oral Rehydration Solutions. Journal of Pediatric Gastroenterology and Nutrition. 27(1). 17–22. 7 indexed citations
20.
Wapnir, R A, Mark A. Wingertzahn, & Saul Teichberg. (1997). L-arginine in low concentration improves rat intestinal water and sodium absorption from oral rehydration solutions.. Gut. 40(5). 602–607. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Salvatore Barberi Breakdown of academic impact, for papers by Giuseppe Di Cara Breakdown of academic impact, for papers by A. Lanteaume Breakdown of academic impact, for papers by Mar Guilarte Breakdown of academic impact, for papers by Lyndon E. Mansfield Breakdown of academic impact, for papers by K. de Vries Breakdown of academic impact, for papers by Hanne Vanheel Breakdown of academic impact, for papers by Robert J. Dockhorn Breakdown of academic impact, for papers by T. Frediani Breakdown of academic impact, for papers by Ko‐Huang Lue
Rankless by CCL
2026